Next generation biomarkers in prostate cancer

Frontiers in Bioscience - Landmark

Volumn 21, Issue 2, 2016, Pages 328-342

  Locke, Jennifer A ^a   Black, Peter C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarkers; Castration resistant prostate cancer; Genomic classifiers; Prostate cancer

Indexed keywords

TUMOR MARKER;

HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; URINE;

BIOMARKERS, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 85016140999     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4391     Document Type: Article

References (95)

1. F. H. Schroder, ERSPC, PLCO studies and critique of cochrane review 2013, Recent Results Cancer Res 202, 59-63 (2014) DOI:10.1007/978-3-642-45195-9-7
2. F. H. Schroder, Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC), Can J Urol 12 Suppl 1, 2-6; discussion 92-3 (2005)
3. G. L. Andriole Jr, PSA screening and prostate cancer risk reduction, Urol Oncol 30, 936-937 (2012) DOI: 10.1016/j.urolonc.2012.09.009
4. A. F. Nash and I. Melezinek: The role of prostate specific antigen measurement in the detection and management of prostate cancer, Endocr Relat Cancer 7, 37-51 (2000) DOI: 10.1677/erc.0.0070037
5. A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer, J Urol 150, 110-114 (1993)
6. S. P. Porten, J. M. Whitson, J. E. Cowan, M. R. Cooperberg, K. Shinohara, N. Perez, K. L. Greene, M. V. Meng and P. R. Carroll: Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance, J Clin Oncol 29, 2795-2800 (2011) DOI: 10.1200/JCO.2010.33.0134
7. J. J. Tosoian, E. JohnBull, B. J. Trock, P. Landis, J. I. Epstein, A. W. Partin, P. C. Walsh and H. B. Carter: Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance, J Urol 190, 1218-1222 (2013) DOI: 10.1016/j.juro.2013.04.071
8. G. Losco, R. Studd and T. Blackmore: Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate, BJU Int 113 Suppl 2, 69-72 (2014) DOI: 10.1111/bju.12590
9. S. S. Ubee, R. R. Marri and S. J. Srirangam: Pain related and overall morbidity with TRUS guided prostate biopsy-a prospective study, Int Braz J Urol 39, 671-674 (2013) DOI: 10.1590/S1677-5538. IBJU.2013.05.09
10. M. Bolla, H. van Poppel, B. Tombal, K. Vekemans, L. Da Pozzo, T. M. de Reijke, A. Verbaeys, J. F. Bosset, R. van Velthoven, M. Colombel, C. van de Beek, P. Verhagen, A. van den Bergh, C. Sternberg, T. Gasser, G. van Tienhoven, P. Scalliet, K. Haustermans, L. Collette and European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911), Lancet 380, 2018-2027 (2012) DOI: 10.1016/S0140-6736 (12) 61253-7
11. T. Wiegel, D. Bartkowiak, D. Bottke, C. Bronner, U. Steiner, A. Siegmann, R. Golz, S. Storkel, N. Willich, A. Semjonow, M. Stockle, C. Rube, U. Rebmann, T. Kalble, H. J. Feldmann, M. Wirth, R. Hofmann, R. Engenhart-Cabillic, A. Hinke, W. Hinkelbein and K. Miller: Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial, Eur Urol (2014) DOI: 10.1016/j.eururo.2014.03.011
12. U. Ganswindt, A. Stenzl, M. Bamberg and C. Belka: Adjuvant radiotherapy for patients with locally advanced prostate cancer-a new standard? Eur Urol 54, 528-542 (2008) DOI: 10.1016/j.eururo.2008.06.059
13. I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, E. Canby-Hagino and E. D. Crawford: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial, J Urol 181, 956-962 (2009) DOI: 10.1016/j.juro.2008.11.032
14. A. V. D'Amico, Adjuvant versus salvage post-prostatectomy radiation therapy: a critical review of the evidence, J Urol 190, 450-451 (2013) DOI: 10.1016/j.juro.2013.05.028
15. N. Bhojani, U. Capitanio, N. Suardi, C. Jeldres, H. Isbarn, S. F. Shariat, M. Graefen, P. Arjane, A. Duclos, J. B. Lattouf, F. Saad, L. Valiquette, F. Montorsi, P. Perrotte and P. I. Karakiewicz: The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17, 845 patients, Int J Radiat Oncol Biol Phys 76, 342-348 (2010) DOI: 10.1016/j.ijrobp. 2009.02.011
16. S. T. Peeters, W. D. Heemsbergen, W. L. van Putten, A. Slot, H. Tabak, J. W. Mens, J. V. Lebesque and P. C. Koper: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy, Int J Radiat Oncol Biol Phys 61, 1019-1034 (2005) DOI: 10.1016/j.ijrobp. 2004.07.715
17. G. C. Barnett, C. E. Coles, R. M. Elliott, C. Baynes, C. Luccarini, D. Conroy, J. S. Wilkinson, J. Tyrer, V. Misra, R. Platte, S. L. Gulliford, M. R. Sydes, E. Hall, S. M. Bentzen, D. P. Dearnaley, N. G. Burnet, P. D. Pharoah, A. M. Dunning and C. M. West: Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study, Lancet Oncol 13, 65-77 (2012) DOI: 10.1016/S1470-2045 (11) 70302-3
18. C. M. West and G. C. Barnett: Genetics and genomics of radiotherapy toxicity: towards prediction, Genome Med 3, 52 (2011) DOI: 10.1186/gm268
19. D. E. Rathkopf, M. R. Smith, J. S. de Bono, C. J. Logothetis, N. D. Shore, P. de Souza, K. Fizazi, P. F. Mulders, P. Mainwaring, J. D. Hainsworth, T. M. Beer, S. North, Y. Fradet, H. Van Poppel, J. Carles, T. W. Flaig, E. Efstathiou, E. Y. Yu, C. S. Higano, M. E. Taplin, T. W. Griffin, M. B. Todd, M. K. Yu, Y. C. Park, T. Kheoh, E. J. Small, H. I. Scher, A. Molina, C. J. Ryan and F. Saad: Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302), Eur Urol (2014) DOI: 10.1016/j.eururo.2014.02.056
20. H. I. Scher, K. Fizazi, F. Saad, M. E. Taplin, C. N. Sternberg, K. Miller, R. de Wit, P. Mulders, K. N. Chi, N. D. Shore, A. J. Armstrong, T. W. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J. D. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. S. de Bono and AFFIRM Investigators: Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med 367, 1187-1197 (2012) DOI: 10.1056/NEJMoa1207506
21. J. S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. P. Machiels, I. Kocak, G. Gravis, I. Bodrogi, M. J. Mackenzie, L. Shen, M. Roessner, S. Gupta, A. O. Sartor and TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial, Lancet 376, 1147-1154 (2010) DOI: 10.1016/S0140-6736 (10) 61389-X
22. C. Parker and O. Sartor: Radium-223 in prostate cancer, N Engl J Med 369, 1659-1660 (2013) DOI: 10.1056/NEJMc1310231
23. P. W. Kantoff, C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, Y. Xu, M. W. Frohlich, P. F. Schellhammer and IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med 363, 411-422 (2010) DOI: 10.1056/NEJMoa1001294
24. D. Abdueva, M. Wing, B. Schaub, T. Triche and E. Davicioni: Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays, J Mol Diagn 12, 409-417 (2010) DOI: 10.2353/jmoldx.2010.090155
25. J. T. Bishoff, S. J. Freedland, L. Gerber, P. Tennstedt, J. Reid, W. Welbourn, M. Graefen, Z. Sangale, E. Tikishvili, J. Park, A. Younus, A. Gutin, J. S. Lanchbury, G. Sauter, M. Brawer, S. Stone and T. Schlomm: Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy, J Urol 192, 409-414 (2014) DOI: 10.1016/j.juro.2014.02.003
26. Jack Cuzick, Steven Stone, Zi Hua Yang, Julia Reid, Gabrielle Fisher, Daniel Berney, Luis Beltran, Henrik Moller, David Greenberg, Michael Brawer, Alexander Gutin, Jerry Lanchbury, Peter Scardino, Validation of A 46-Gene Cell Cycle Progression (CCP) RNA Signature For Predicting Prostate Cancer Death in A Conservatively Managed Watchful Waiting Needle Biopsy Cohort, American Urological Association Annual Meeting (2014) DOI:10.1016/j.juro.2014.02.2520
27. M. R. Cooperberg, E. Davicioni, A. Crisan, R. B. Jenkins, M. Ghadessi and R. J. Karnes: Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a Highrisk Prostatectomy Cohort, Eur Urol (2014)
28. E. A. Klein, M. R. Cooperberg, C. Magi-Galluzzi, J. P. Simko, S. M. Falzarano, T. Maddala, J. M. Chan, J. Li, J. E. Cowan, A. C. Tsiatis, D. B. Cherbavaz, R. J. Pelham, I. Tenggara-Hunter, F. L. Baehner, D. Knezevic, P. G. Febbo, S. Shak, M. W. Kattan, M. Lee and P. R. Carroll: A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling, Eur Urol (2014)
29. R. Jin, Y. Yi, F. E. Yull, T. S. Blackwell, P. E. Clark, T. Koyama, J. A. Smith Jr and R. J. Matusik: NF-kappaB gene signature predicts prostate cancer progression, Cancer Res 74, 2763-2772 (2014) DOI: 10.1158/0008-5472. CAN-13-2543
30. N. Erho, A. Crisan, I. A. Vergara, A. P. Mitra, M. Ghadessi, C. Buerki, E. J. Bergstralh, T. Kollmeyer, S. Fink, Z. Haddad, B. Zimmermann, T. Sierocinski, K. V. Ballman, T. J. Triche, P. C. Black, R. J. Karnes, G. Klee, E. Davicioni and R. B. Jenkins: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy, PLoS One 8, e66855 (2013)
31. Matthew R. Cooperberg, Stephen J. Freedland, Thorsten Schlomm, Julia E. Reid, Steven Stone, Michael K. Brawer, Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7, ASCO (2014)
32. A. E. Ross, F. Y. Feng, M. Ghadessi, N. Erho, A. Crisan, C. Buerki, D. Sundi, A. P. Mitra, I. A. Vergara, D. J. Thompson, T. J. Triche, E. Davicioni, E. J. Bergstralh, R. B. Jenkins, R. J. Karnes and E. M. Schaeffer: A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy, Prostate Cancer Prostatic Dis 17, 64-69 (2014) DOI: 10.1.038/pcan. 2013.4.9
33. R. J. Karnes, E. J. Bergstralh, E. Davicioni, M. Ghadessi, C. Buerki, A. P. Mitra, A. Crisan, N. Erho, I. A. Vergara, L. L. Lam, R. Carlson, D. J. Thompson, Z. Haddad, B. Zimmermann, T. Sierocinski, T. J. Triche, T. Kollmeyer, K. V. Ballman, P. C. Black, G. G. Klee and R. B. Jenkins: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population, J Urol 190, 2047-2053 (2013) DOI: 10.1016/j.juro.2013.06.017
34. R. B. Den, F. Y. Feng, T. N. Showalter, M. V. Mishra, E. J. Trabulsi, C. D. Lallas, L. G. Gomella, W. K. Kelly, R. C. Birbe, P. A. McCue, M. Ghadessi, K. Yousefi, E. Davicioni, K. E. Knudsen and A. P. Dicker: Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy, Int J Radiat Oncol Biol Phys 89, 1038-1046 (2014) DOI: 10.1016/j.ijrobp. 2014.04.052
35. H. J. Folse, L. E. Green, A. Kress, R. Allman and T. A. Dinh: Cost-effectiveness of a genetic test for breast cancer risk, Cancer Prev Res (Phila) 6, 1328-1336 (2013) DOI: 10.1158/1940-6207. CAPR-13-0056
36. T. Nordstrom, A. Vickers, M. Assel, H. Lilja, H. Gronberg and M. Eklund: Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer, Eur Urol (2014) DOI: 10.1016/j.eururo.2014.08.010
37. G. Guazzoni, M. Lazzeri, L. Nava, G. Lughezzani, A. Larcher, V. Scattoni, G. M. Gadda, V. Bini, A. Cestari, N. M. Buffi, M. Freschi, P. Rigatti and F. Montorsi: Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer, Eur Urol 61, 455-466 (2012) DOI: 10.1016/j.eururo.2011.10.038
38. R. Mahn, L. C. Heukamp, S. Rogenhofer, A. von Ruecker, S. C. Muller and J. Ellinger: Circulating microRNAs (miRNA) in serum of patients with prostate cancer, Urology 77, 1265.e9-1265.1.6 (2011)
39. Y. Li and K. V. Kowdley: Method for microRNA isolation from clinical serum samples, Anal Biochem 431, 69-75 (2012) DOI: 10.1016/j.ab.2012.09.007
40. R. J. Bryant, T. Pawlowski, J. W. Catto, G. Marsden, R. L. Vessella, B. Rhees, C. Kuslich, T. Visakorpi and F. C. Hamdy: Changes in circulating microRNA levels associated with prostate cancer, Br J Cancer 106, 768-774 (2012) DOI: 10.1038/bjc.2011.595
41. A. M. Westermann, D. Schmidt, S. Holdenrieder, R. Moritz, A. Semjonow, M. Schmidt, G. Kristiansen, S. C. Muller and J. Ellinger: Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study, Anticancer Res 34, 665-669 (2014)
42. H. C. Nguyen, W. Xie, M. Yang, C. L. Hsieh, S. Drouin, G. S. Lee and P. W. Kantoff: Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer, Prostate 73, 346-354 (2013) DOI: 10.1002/pros.22572
43. Z. Lichner, A. Fendler, C. Saleh, A. N. Nasser, D. Boles, S. Al-Haddad, P. Kupchak, M. Dharsee, P. S. Nuin, K. R. Evans, K. Jung, C. Stephan, N. E. Fleshner and G. M. Yousef: MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer, Clin Chem 59, 1595-1603 (2013) DOI: 10.1373/clinchem.2013.205450
44. H. M. Lin, L. Castillo, K. L. Mahon, K. Chiam, B. Y. Lee, Q. Nguyen, M. J. Boyer, M. R. Stockler, N. Pavlakis, G. Marx, G. Mallesara, H. Gurney, S. J. Clark, A. Swarbrick, R. J. Daly and L. G. Horvath: Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer, Br J Cancer 110, 2462-2471 (2014) DOI: 10.1038/bjc.2014.181
45. L. De Mattos-Arruda, J. Cortes, L. Santarpia, A. Vivancos, J. Tabernero, J. S. Reis-Filho and J. Seoane: Circulating tumour cells and cellfree DNA as tools for managing breast cancer, Nat Rev Clin Oncol 10, 377-389 (2013) DOI: 10.1038/nrclinonc.2013.80
46. J. Feng, F. Gang, X. Li, T. Jin, H. Houbao, C. Yu and L. Guorong: Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen, Int Urol Nephrol 45, 1023-1028 (2013) DOI: 10.1007/s11255-013-0491-2
47. H. Schwarzenbach, C. Alix-Panabieres, I. Muller, N. Letang, J. P. Vendrell, X. Rebillard and K. PanTel: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer, Clin Cancer Res 15, 1032-1038 (2009) DOI: 10.1158/1078-0432. CCR-08-1910
48. S. J. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, O. M. Rueda, S. F. Chin, M. J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas and N. Rosenfeld: Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med 368, 1199-1209 (2013) DOI: 10.1056/NEJMoa1213261
49. M. L. Wroclawski, A. Serpa-Neto, F. L. Fonseca, O. Castro-Neves-Neto, A. S. Pompeo, M. T. Machado, A. C. Pompeo and A. del Giglio: Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients, Tumour Biol 34, 2921-2927 (2013) DOI: 10.1007/s13277-013-0854-4
50. Arun Azad, Stanislav Volik, Alexander Wyatt, Anne Haegert, Colin Collins, Kim N. Chi, Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza), DOI: content/133137-144 (2014)
51. S. Carreira, A. Romanel, J. Goodall, E. Grist, R. Ferraldeschi, S. Miranda, D. Prandi, D. Lorente, J. S. Frenel, C. Pezaro, A. Omlin, D. N. Rodrigues, P. Flohr, N. Tunariu, J. S. de Bono, F. Demichelis and G. Attard: Tumor clone dynamics in lethal prostate cancer, Sci Transl Med 6, 254ra125 (2014) DOI: 10.1126/scitranslmed.3009448
52. J. D. Joseph, N. Lu, J. Qian, J. Sensintaffar, G. Shao, D. Brigham, M. Moon, E. C. Maneval, I. Chen, B. Darimont and J. H. Hager: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509, Cancer Discov 3, 1020-1029 (2013) DOI: 10.1158/2159-8290. CD-13-0226
53. A. M. Barradas and L. W. Terstappen: Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis, Cancers (Basel) 5, 1619-1642 (2013) DOI: 10.3390/cancers5041619
54. J. Kling, Beyond counting tumor cells, Nat Biotechnol 30, 578-580 (2012) DOI:10.1038/nbt.2295 DOI: 10.1038/nbt1212-1249b
55. B. K. Lin, S. M. McFaul, C. Jin, P. C. Black and H. Ma: Highly selective biomechanical separation of cancer cells from leukocytes using microfluidic ratchets and hydrodynamic concentrator, Biomicrofluidics 7, 34114 (2013) DOI: 10.1063/1.4812688
56. K. K. Khurana, R. Grane, E. C. Borden and E. A. Klein: Prevalence of circulating tumor cells in localized prostate cancer, Curr Urol 7, 65-69 (2013) DOI: 10.1159/000356251
57. J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W. Terstappen, K. J. Pienta and D. Raghavan: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res 14, 6302-6309 (2008) DOI: 10.1158/1078-0432. CCR-08-0872
58. H. I. Scher, X. Jia, J. S. de Bono, M. Fleisher, K. J. Pienta, D. Raghavan and G. Heller: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data, Lancet Oncol 10, 233-239 (2009) DOI: 10.1016/S1470-2045 (08) 70340-1
59. D. C. Danila, A. Anand, C. C. Sung, G. Heller, M. A. Leversha, L. Cao, H. Lilja, A. Molina, C. L. Sawyers, M. Fleisher and H. I. Scher: TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate, Eur Urol 60, 897-904 (2011) DOI: 10.1016/j.eururo.2011.07.011
60. D. Lorente, J. Mateo and J. S. de Bono: Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer, Am Soc Clin Oncol Educ Book, e197-203 (2014) DOI: 10.14694/EdBook-AM.2014.34.e197
61. D. T. Miyamoto, L. V. Sequist and R. J. Lee: Circulating tumour cells-monitoring treatment response in prostate cancer, Nat Rev Clin Oncol 11, 401-412 (2014) DOI: 10.1038/nrclinonc.2014.82
62. E. S. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa, J. C. Roeser, Y. Chen, T. A. Mohammad, Y. Chen, H. L. Fedor, T. L. Lotan, Q. Zheng, A. M. De Marzo, J. T. Isaacs, W. B. Isaacs, R. Nadal, C. J. Paller, S. R. Denmeade, M. A. Carducci, M. A. Eisenberger and J. Luo: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med 371, 1028-1038 (2014) DOI: 10.1056/NEJMoa1315815
63. L. S. Marks, Y. Fradet, I. L. Deras, A. Blase, J. Mathis, S. M. Aubin, A. T. Cancio, M. Desaulniers, W. J. Ellis, H. Rittenhouse and J. Groskopf: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology 69, 532-535 (2007) DOI: 10.1016/j.urology.2006.12.014
64. I. L. Deras, S. M. Aubin, A. Blase, J. R. Day, S. Koo, A. W. Partin, W. J. Ellis, L. S. Marks, Y. Fradet, H. Rittenhouse and J. Groskopf: PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol 179, 1587-1592 (2008) DOI: 10.1016/j.juro.2007.11.038
65. D. W. Lin, L. F. Newcomb, E. C. Brown, J. D. Brooks, P. R. Carroll, Z. Feng, M. E. Gleave, R. S. Lance, M. G. Sanda, I. M. Thompson, J. T. Wei, P. S. Nelson and Canary Prostate Active Surveillance Study Investigators: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study, Clin Cancer Res 19, 2442-2450 (2013) DOI: 10.1158/1078-0432. CCR-12-3283
66. S. A. Tomlins, B. Laxman, S. Varambally, X. Cao, J. Yu, B. E. Helgeson, Q. Cao, J. R. Prensner, M. A. Rubin, R. B. Shah, R. Mehra and A. M. Chinnaiyan: Role of the TMPRSS2-ERG gene fusion in prostate cancer, Neoplasia 10, 177-188 (2008) DOI: 10.1593/neo.07822
67. G. H. Leyten, D. Hessels, S. A. Jannink, F. P. Smit, H. de Jong, E. B. Cornel, T. M. de Reijke, H. Vergunst, P. Kil, B. C. Knipscheer, I. M. van Oort, P. F. Mulders, C. A. Hulsbergen-van de Kaa and J. A. Schalken: Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer, Eur Urol 65, 534-542 (2014) DOI: 10.1016/j.eururo.2012.11.014
68. J. E. McDunn, Z. Li, K. P. Adam, B. P. Neri, R. L. Wolfert, M. V. Milburn, Y. Lotan and T. M. Wheeler: Metabolomic signatures of aggressive prostate cancer, Prostate 73, 1547-1560 (2013) DOI: 10.1002/pros.22704
69. S. Koutros, T. E. Meyer, S. D. Fox, H. J. Issaq, T. D. Veenstra, W. Y. Huang, K. Yu, D. Albanes, L. W. Chu, G. Andriole, R. N. Hoover, A. W. Hsing and S. I. Berndt: Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, Carcinogenesis 34, 2281-2285 (2013) DOI: 10.1093/carcin/bgt176
70. A. Sciarra, V. Panebianco, S. Cattarino, G. M. Busetto, E. De Berardinis, M. Ciccariello, V. Gentile and S. Salciccia: Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy, BJU Int 110, 1661-1665 (2012) DOI: 10.1111/j.1464-410X.2012.11146.x
71. J. Ferda, J. Kastner, M. Hora, O. Hes, J. Finek, O. Topolcan and B. Kreuzberg: A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy, Anticancer Res 33, 2791-2795 (2013)
72. C. M. Hoeks, M. G. Schouten, J. G. Bomers, S. P. Hoogendoorn, C. A. Hulsbergen-van de Kaa, T. Hambrock, H. Vergunst, J. P. Sedelaar, J. J. Futterer and J. O. Barentsz: Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers, Eur Urol 62, 902-909 (2012) DOI: 10.1016/j.eururo.2012.01.047
73. T. Hambrock, D. M. Somford, C. Hoeks, S. A. Bouwense, H. Huisman, D. Yakar, I. M. van Oort, J. A. Witjes, J. J. Futterer and J. O. Barentsz: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen, J Urol 183, 520-527 (2010) DOI: 10.1016/j.juro.2009.10.022
74. C. M. Hoeks, D. M. Somford, I. M. van Oort, H. Vergunst, J. R. Oddens, G. A. Smits, M. J. Roobol, M. Bul, T. Hambrock, J. A. Witjes, J. J. Futterer, C. A. Hulsbergen-van de Kaa and J. O. Barentsz: Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study, Invest Radiol 49, 165-172 (2014) DOI: 10.1097/RLI.0000000000000008
75. E. Baco, O. Ukimura, E. Rud, L. Vlatkovic, A. Svindland, M. Aron, S. Palmer, T. Matsugasumi, A. Marien, J. C. Bernhard, J. C. Rewcastle, H. B. Eggesbo and I. S. Gill: Magnetic Resonance Imaging-Transectal Ultrasound Image-fusion Biopsies Accurately Characterize the Index Tumor: Correlation with Step-sectioned Radical Prostatectomy Specimens in 135 Patients, Eur Urol (2014)
76. E. Rud, D. Klotz, K. Rennesund, E. Baco, T. E. Johansen, L. M. Diep, A. Svindland, L. M. Eri and H. B. Eggesbo: Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer, World J Urol (2014). DOI: 10.1007/s00345-014-1362-x
77. D. M. Somford, E. H. Hamoen, J. J. Futterer, J. P. van Basten, C. A. Hulsbergenvan de Kaa, W. Vreuls, I. M. van Oort, H. Vergunst, L. A. Kiemeney, J. O. Barentsz and J. A. Witjes: The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer, J Urol 190, 1728-1734 (2013) DOI: 10.1016/j.juro.2013.05.021
78. S. C. Agner, M. A. Rosen, S. Englander, J. E. Tomaszewski, M. D. Feldman, P. Zhang, C. Mies, M. D. Schnall and A. Madabhushi: Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study, Radiology 272, 91-99 (2014) DOI: 10.1148/radiol.14121031
79. N. F. Haq, P. Kozlowski, E. C. Jones, S. D. Chang, S. L. Goldenberg and M. Moradi: A data-driven approach to prostate cancer detection from dynamic contrast enhanced MRI, Comput Med Imaging Graph (2014)
80. V. Nerich, E. Curtit, F. Bazan, P. Montcuquet, C. Villanueva, L. Chaigneau, L. Cals, N. Meneveau, E. Dobi, H. Altmotlak, M. P. Algros, M. J. Choulot, G. Nallet, S. Limat, S. Mansion and X. Pivot: Economic assessment of the routine use of Oncotype DX (R) assay for early breast cancer in Franche-Comte region, Bull Cancer 101, 681-689 (2014)
81. S. Holt, G. Bertelli, I. Humphreys, W. Valentine, S. Durrani, D. Pudney, M. Rolles, M. Moe, S. Khawaja, Y. Sharaiha, E. Brinkworth, S. Whelan, S. Jones, H. Bennett and C. J. Phillips: A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U. K, Br J Cancer 108, 2250-2258 (2013) DOI: 10.1038/bjc.2013.207
82. J. Cuzick, D. M. Berney, G. Fisher, D. Mesher, H. Moller, J. E. Reid, M. Perry, J. Park, A. Younus, A. Gutin, C. S. Foster, P. Scardino, J. S. Lanchbury, S. Stone and Transatlantic Prostate Group: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort, Br J Cancer 106, 1095-1099 (2012) DOI: 10.1038/bjc.2012.39
83. M. R. Cooperberg, J. P. Simko, J. E. Cowan, J. E. Reid, A. Djalilvand, S. Bhatnagar, A. Gutin, J. S. Lanchbury, G. P. Swanson, S. Stone and P. R. Carroll: Validation of a cellcycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort, J Clin Oncol 31, 1428-1434 (2013) DOI: 10.1200/JCO.2012.46.4396
84. S. J. Freedland, L. Gerber, J. Reid, W. Welbourn, E. Tikishvili, J. Park, A. Younus, A. Gutin, Z. Sangale, J. S. Lanchbury, J. K. Salama and S. Stone: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy, Int J Radiat Oncol Biol Phys 86, 848-853 (2013) DOI: 10.1016/j.ijrobp. 2013.04.043
85. D. Knezevic, A. D. Goddard, N. Natraj, D. B. Cherbavaz, K. M. Clark-Langone, J. Snable, D. Watson, S. M. Falzarano, C. Magi-Galluzzi, E. A. Klein and C. Quale: Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies, BMC Genomics 14, 690-2164-14-690 (2013)
86. R. B. Den, F. Y. Feng, T. N. Showalter, M. V. Mishra, E. J. Trabulsi, C. D. Lallas, L. G. Gomella, W. K. Kelly, R. C. Birbe, P. A. McCue, M. Ghadessi, K. Yousefi, E. Davicioni, K. E. Knudsen and A. P. Dicker: Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy, Int J Radiat Oncol Biol Phys 89, 1038-1046 (2014) DOI: 10.1016/j.ijrobp. 2014.04.052
87. K. K. Badani, D. J. Thompson, G. Brown, D. Holmes, N. Kella, D. Albala, A. Singh, C. Buerki, E. Davicioni and J. Hornberger: Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery, BJU Int (2014)
88. I. Casanova-Salas, J. Rubio-Briones, A. Calatrava, C. Mancarella, E. Masia, J. Casanova, A. Fernandez-Serra, L. Rubio, M. Ramirez-Backhaus, A. Arminan, J. Dominguez-Escrig, F. Martinez, Z. Garcia-Casado, K. Scotlandi, M. J. Vicent and J. A. Lopez-Guerrero: Identification of miR-187 and miR-182 as Biomarkers of Early Diagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy, J Urol (2014)
89. D. C. Danila, M. Fleisher and H. I. Scher: Circulating tumor cells as biomarkers in prostate cancer, Clin Cancer Res 17, 3903-3912 (2011) DOI: 10.1158/1078-0432. CCR-10-2650
90. O. B. Goodman Jr, L. M. Fink, J. T. Symanowski, B. Wong, B. Grobaski, D. Pomerantz, Y. Ma, D. C. Ward and N. J. Vogelzang: Circulating tumor cells in patients with castrationresistant prostate cancer baseline values and correlation with prognostic factors, Cancer Epidemiol Biomarkers Prev 18, 1904-1913 (2009) DOI: 10.1158/1055-9965. EPI-08-1173
91. J. Groskopf, S. M. Aubin, I. L. Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, J. Mathis, J. Pham, T. Meyer, M. Cass, P. Hodge, M. L. Macairan, L. S. Marks and H. Rittenhouse: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin Chem 52, 1089-1095 (2006) DOI: 10.1373/clinchem.2005.063289
92. D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel and J. A. Schalken: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer, Clin Cancer Res 13, 5103-5108 (2007) DOI: 10.1158/1078-0432. CCR-07-0700
93. E. Thysell, I. Surowiec, E. Hornberg, S. Crnalic, A. Widmark, A. I. Johansson, P. Stattin, A. Bergh, T. Moritz, H. Antti and P. Wikstrom: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol, PLoS One 5, e14175 (2010) DOI: 10.1371/journal.pone.0014175
94. Y. H. Song, M. Shiota, K. Kuroiwa, S. Naito and Y. Oda: The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer, Mod Pathol 24, 1272-1280 (2011) DOI: 10.1038/modpathol.2011.76
95. T. B. Dorff, T. W. Flaig, C. M. Tangen, M. H. Hussain, G. P. Swanson, D. P. Wood Jr, W. A. Sakr, N. A. Dawson, N. B. Haas, E. D. Crawford, N. J. Vogelzang, I. M. Thompson and L. M. Glode: Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study, J Clin Oncol 29, 2040-2045 (2011) DOI: 10.1200/JCO.2010.32.2776